Abstract
In order to clarify the role of lipid metabolism in the pathogenesis of psoriasis, niceritrol, a potent hypolipidemic agent, was administered orally for 4∼10 weeks to 28 psoriasis patients with 14 cases being treated by combination and conventional therapy and 14 cases being given monotherapy. Before treatment with niceritrol, serum lipid abnormality was observed in 17 patients (68.0%). In addition, the higher the serum triglyceride (TG) levels in these patients, the more severe the skin lesions were (p<0.01). After treating 24 patients with niceritrol (85.7%), an improvement of the skin lesions was observed along with an improvement of serum lipids. These findings suggest that niceritrol may be useful in treating psoriasis, especially in cases complicated with hyperlipidemia.
